Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction (ACTonLVT)
ST-segment Elevation Myocardial Infarction (STEMI), Left Ventricular Thrombus
About this trial
This is an interventional treatment trial for ST-segment Elevation Myocardial Infarction (STEMI) focused on measuring STEMI, LVT, Anticoagulation
Eligibility Criteria
Inclusion Criteria: Established ST segment elevation myocardial infarction within 7 days Left ventricular thrombus (LVT) is detected by either cardiac magnetic resonance (CMR) or TTE. Ongoing treatment with dual anti-platelet therapy according to ESC/AHA guidelines at the time of randomization Exclusion Criteria: Clinically or hemodynamically unstable planed major surgeon such as CABG or Valve replacement within next 12 months Concomitant condition that requires anti- coagulation therapy, such as AF, DVT. Any contraindication of anticoagulant therapy History of intracranial hemorrhage; Woman who is currently pregnant, or breastfeeding serious impaired renal and liver functions life expectancy less than 1 year can not provide consent
Sites / Locations
- Jilin universityRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
intervention
control
patient will receive dual antiplatelet therapy, the choose of p2Y12 inhibitor is at the discretion of the clinician. in addition the patient will receive rivaroxaban 15mg daily in addition to the dual antiplatelet therapy.
patient will receive dual antiplatelet therapy, the choose of p2Y12 inhibitor is at the discretion of the clinician.